Jazz Pharmaceuticals (JAZZ) Reports In-Line Q4 EPS, FY Guidance Comes in Light
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- AMD stock jumps as chip rally builds ahead of summit
Jazz Pharmaceuticals' (JAZZ) Weak 4Q Results and 2016 Guidance Has Mizuho Securities Sidelined - PT to $124
February 24, 2016 6:54 AM ESTMizuho Securities reiterated a Neutral rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $124.00 (from $140.00), following the company's 4Q earnings report. JAZZ reported revenue of $340.9M and EPS of $2.60 versus consensus estimates of $350.8M and $2.60. Management also issued below-consensus 2016 guidance of... More
